HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lecia V Sequist Selected Research

Diarrhea

6/2023Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.
9/2013Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
9/2013Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
6/2010Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lecia V Sequist Research Topics

Disease

96Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 08/2005
90Neoplasms (Cancer)
04/2024 - 07/2006
62Lung Neoplasms (Lung Cancer)
11/2023 - 07/2006
21Disease Progression
01/2023 - 08/2009
14Neoplasm Metastasis (Metastasis)
01/2022 - 12/2007
13Adenocarcinoma of Lung
06/2023 - 07/2007
10Circulating Neoplastic Cells
03/2024 - 07/2008
6Adenocarcinoma
01/2019 - 07/2007
6Prostatic Neoplasms (Prostate Cancer)
01/2018 - 03/2010
5Fatigue
06/2023 - 09/2013
5Dyspnea (Shortness of Breath)
06/2023 - 09/2013
4Diarrhea
06/2023 - 06/2010
4Cough
06/2023 - 09/2013
4Exanthema (Rash)
06/2023 - 09/2013
4Pain (Aches)
06/2023 - 09/2013
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2021 - 10/2010
4Melanoma (Melanoma, Malignant)
01/2018 - 07/2012
4Brain Neoplasms (Brain Tumor)
01/2018 - 11/2014
3Acne Vulgaris
06/2023 - 09/2013
3Stomatitis
06/2023 - 09/2013
3Nausea
06/2023 - 09/2013
3Central Nervous System Diseases (CNS Diseases)
06/2022 - 01/2018
3Pneumonia (Pneumonitis)
01/2021 - 05/2008
3Epilepsy (Aura)
01/2019 - 04/2017
2Lymphoma (Lymphomas)
04/2024 - 05/2012
2Carcinoma (Carcinomatosis)
04/2024 - 12/2012
2Sarcoma (Soft Tissue Sarcoma)
01/2022 - 02/2015
2Acute Kidney Injury (Acute Renal Failure)
01/2020 - 11/2016
2Neutropenia
11/2016 - 02/2015
1Neuroendocrine Carcinoma
04/2024
1Edema (Dropsy)
08/2023
1Genomic Instability
08/2023
1COVID-19
01/2021
1medullary Thyroid cancer
01/2020

Drug/Important Bio-Agent (IBA)

74ErbB Receptors (EGF Receptor)IBA
01/2023 - 08/2005
49Tyrosine Kinase InhibitorsIBA
05/2024 - 01/2007
22Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2019 - 07/2006
15RNA (Ribonucleic Acid)IBA
03/2024 - 03/2010
14osimertinibIBA
04/2024 - 04/2016
14AfatinibIBA
06/2023 - 05/2012
11Biomarkers (Surrogate Marker)IBA
01/2023 - 12/2007
11Gefitinib (Iressa)FDA Link
01/2019 - 07/2006
10Phosphotransferases (Kinase)IBA
01/2022 - 08/2005
9CrizotinibIBA
08/2023 - 06/2010
9Pemetrexed (MTA)FDA Link
06/2023 - 10/2008
9PlatinumIBA
01/2022 - 02/2010
8Cisplatin (Platino)FDA LinkGeneric
06/2023 - 11/2008
8Anaplastic Lymphoma KinaseIBA
01/2020 - 06/2010
7Proteins (Proteins, Gene)FDA Link
03/2024 - 06/2007
7DNA (Deoxyribonucleic Acid)IBA
03/2024 - 05/2008
7rociletinibIBA
11/2018 - 01/2015
5Immune Checkpoint InhibitorsIBA
01/2021 - 06/2015
4Circulating Tumor DNAIBA
01/2020 - 03/2016
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2018 - 07/2012
4ARQ 197IBA
01/2018 - 08/2011
3alectinibIBA
08/2023 - 10/2016
3lorlatinibIBA
10/2022 - 01/2021
3Bevacizumab (Avastin)FDA Link
01/2022 - 10/2008
3nazartinibIBA
01/2022 - 01/2018
3Docetaxel (Taxotere)FDA Link
01/2019 - 01/2015
3Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA
01/2019 - 12/2012
3Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2019 - 03/2013
3pembrolizumabIBA
01/2019 - 11/2016
3Androgen Receptors (Androgen Receptor)IBA
11/2017 - 11/2012
3Carboplatin (JM8)FDA LinkGeneric
11/2016 - 11/2009
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2010 - 07/2006
2capmatinibIBA
08/2023 - 01/2021
21- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA
01/2023 - 01/2020
2cabozantinibIBA
01/2022 - 01/2021
2Cell-Free Nucleic AcidsIBA
01/2020 - 01/2017
2olaparibIBA
10/2019 - 10/2013
2Messenger RNA (mRNA)IBA
01/2019 - 12/2018
25- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA
12/2018 - 01/2018
2NivolumabIBA
10/2018 - 06/2015
2Complement System Proteins (Complement)IBA
12/2017 - 01/2016
2Interleukin-6 (Interleukin 6)IBA
11/2017 - 01/2017
2EpitopesIBA
10/2017 - 04/2013
2Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
01/2017 - 12/2014
2Hydroxychloroquine (Plaquenil)FDA LinkGeneric
10/2015 - 10/2012
2AndrogensIBA
09/2015 - 11/2012
2Heat-Shock Proteins (Heat-Shock Protein)IBA
06/2013 - 11/2010
1GuanineIBA
09/2023
1Poly GIBA
09/2023
1CarcinogensIBA
09/2023
1Cytidine DeaminaseIBA
08/2023
1B7-H1 AntigenIBA
09/2022
1entrectinibIBA
01/2021
1Oxygen (Dioxygen)IBA
01/2021
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2021
1SolventsIBA
01/2020

Therapy/Procedure

75Therapeutics
04/2024 - 07/2006
29Drug Therapy (Chemotherapy)
06/2023 - 02/2007
9Radiotherapy
01/2022 - 02/2015
4Drug Tapering
11/2023 - 06/2010
3Immunotherapy
01/2022 - 01/2015
3Aftercare (After-Treatment)
01/2018 - 06/2007
3Castration
01/2018 - 11/2012
3Lab-On-A-Chip Devices
11/2014 - 07/2008
1Chemoradiotherapy
05/2024
1Surgical Instruments (Clip)
01/2020